
CNTA Stock Forecast & Price Target
CNTA Analyst Ratings
Bulls say
Centessa Pharmaceuticals PLC exhibits strong fundamentals bolstered by its promising pipeline, particularly with ORX750, which is positioned to potentially achieve best-in-class status for treating Narcolepsy Type 1 and other sleep disorders. The company reported a robust cash position of approximately $405 million as of the end of Q2 2025, providing ample runway to support its operations and ongoing clinical development well into mid-2027. Furthermore, the anticipated market dynamics for orexin agonists, alongside a substantial estimated sales potential of around $3.6 billion, underline a significant upside opportunity that enhances the positive outlook for Centessa Pharmaceuticals's stock.
Bears say
Centessa Pharmaceuticals faces significant commercial and competitive risks, primarily due to potential market limitations for its pipeline assets stemming from negotiations with payors and competitive pressures. The presence of high non-responder rates and waning efficacy observed in related clinical programs introduces further uncertainty regarding the effectiveness and market acceptance of its lead candidate, ORX750, for Narcolepsy Type 1. Additionally, the conservative market analysis indicates that the company's current valuation may not accurately reflect the broader potential for its therapeutics, particularly given the implications of late-day efficacy issues and the high variability caused by administration compliance.
This aggregate rating is based on analysts' research of Centessa Pharmaceuticals PLC and is not a guaranteed prediction by Public.com or investment advice.
CNTA Analyst Forecast & Price Prediction
Start investing in CNTA
Order type
Buy in
Order amount
Est. shares
0 shares